. 2020 Sep 14;33(6):e14204. doi: 10.1111/dth.14204

TABLE 4.

Clinical and therapeutic characteristics of hospitalized and not‐hospitalized psoriatic patients with SARS‐Cov2 infection

	Overall n = 32	Hospitalized n = 10 (31.3%)	Not‐hospitalized n = 22 (68.7%)	P‐value
Age (years), mean ± SD	57.6 ± 4.5	64.1 ± 6.5	54.6 ± 5.8	.04
Gender (M), n(%)	22 (68.8)	7 (70.0)	15 (68.2)	.91
Diabetes, n(%)	4 (13.7) ^a	3 (37.5) ^b	1 (4.8) ^c	.07
Hypertension, n(%)	12 (41.4) ^a	5 (62.5) ^b	7 (33.3) ^c	.15
Obesity, n(%)	3 (10.3) ^a	1 (12.5) ^b	2 (9.5) ^c	.28
Cardiocerebrovascular diseases, n(%)	4 (13.7) ^a	1 (12.5) ^b	3 (14.3) ^c	.90
Other, n(%)	4 (13.7) ^a	1 (12.5) ^b	3 (14.3) ^c	.90
>1 comorbidity, n(%)	11 (37.9) ^a	5 (62.5) ^b	6 (28.6) ^c	.09
bDMARDs ^d , n(%)	30 (93.8)	9 (90.0)	21 (95.4)	.55
Anti‐IL23, n(%)	4 (12.5)	1 (10.0)	3 (13.6)	.77
Anti‐IL12/23, n(%)	8 (25.0)	2 (20.0)	6 (27.3)	.66
Anti‐TNFα, n(%)	9 (28.1)	2 (20.0)	7 (31.8)	.49
Anti‐IL17, n(%)	9 (28.1)	3 (30.0)	6 (27.3)	.87
cDMARDs ^d , n(%)	1 (3.0)	1 (10.0)	0 (0)	.13
bDMARDs + cDMARDs, n(%)	1 (3.0)	0 (0)	1 (4.5)	.49

Note: Values are expressed as mean ± SD or n (%).

Abbreviations: bDMARDs, biologic disease‐modifying antirheumatic drugs; cDMARDs, conventional disease‐modifying antirheumatic drugs; M, male.

^{^a}

Missing data for comorbidity modify the total population analyzable on a total population of 29 patients.

^{^b}

Missing data for comorbidity modify the total population analyzable on a total population of 8 patients.

^{^c}

Missing data for comorbidity modify the total population analyzable on a total population of 21 patients.

^{^d}

Numbers indicates patients on bDMARDs or cDMARDs monotherapy.